



HAL
open science

Activation of Nod2 signalling upon Norovirus infection enhances antiviral immunity and susceptibility to colitis

Ghaffar Muharram, Marion Thépaut, Pierre-Emmanuel Lobert, Teddy Grandjean, Olivier Boulard, Myriam Delacre, Emmrich Wakeford, Richard Wheeler, Lionel Franz Poulin, Ivo Gomperts Boneca, et al.

► **To cite this version:**

Ghaffar Muharram, Marion Thépaut, Pierre-Emmanuel Lobert, Teddy Grandjean, Olivier Boulard, et al.. Activation of Nod2 signalling upon Norovirus infection enhances antiviral immunity and susceptibility to colitis. 2023. hal-04101382v1

HAL Id: hal-04101382

<https://hal.science/hal-04101382v1>

Preprint submitted on 22 May 2023 (v1), last revised 30 Oct 2023 (v3)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Activation of Nod2 signalling upon Norovirus infection enhances antiviral immunity and**
2 **susceptibility to colitis**

3
4 **Authors:** Ghaffar Muharram^a, Marion Thépaut^a, Pierre-Emmanuel Lobert^c, Teddy Grandjean^a,
5 Olivier Boulard^b, Myriam Delacre^a, Emmrich Wakeford^a, Richard Wheeler^c, Lionel Franz
6 Poulin^b, Ivo Gomperts Boneca^c, Frank Lafont^a, Marie-Cécile Michallet^d, Didier Hober^c, Ken
7 Cadwell^{f,g,h}, Mathias Chamaillard^b.

8 **Affiliations :**

9 ^aUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL -
10 Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France.

11
12 ^bLaboratory of Cell Physiology, INSERM U1003, University of Lille, Lille, France.

13 ^cUniv Lille, Faculté de Médecine, CHU Lille, Laboratoire de Virologie ULR3610, Lille,
14 France.

15
16 ^dTERI (Tumor Escape, Resistance and Immunity), Centre de recherche en cancérologie de
17 Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Inserm
18 1052, CNRS 5286, 69008 Lyon, France.

19
20 ^eInstitut Pasteur, Université Paris Cité, CNRS UMR6047, INSERM U1306, Unité de Biologie
21 et génétique de la paroi bactérienne, F-75015, Paris, France

22
23 ^fKimmel Center for Biology and Medicine at the Skirball Institute, New York University
24 Grossman School of Medicine, New York, NY 10016, USA

25 ^gDepartment of Microbiology, New York University Grossman School of Medicine, New
26 York, NY 10016, USA

27 ^hDivision of Gastroenterology and Hepatology, Department of Medicine, New York
28 University Langone Health, New York, NY 10016, USA

29
30
31 **Disclosure of interest:**

32 K.C. has received research support from Pfizer, Takeda, Pacific Biosciences, Genentech, and Abbvie;
33 consulted for or received honoraria from Vedanta, Genentech, and Abbvie; and holds U.S. patent
34 10,722,600 and provisional patent 62/935,035 and 63/157,225.

35 **Correspondence should be addressed to:**

36 Mathias Chamaillard, PhD, Phone number: +33359317427, Fax number: +33359317480, E-
37 mail: mathias.chamaillard@inserm.fr

38 Ghaffar Muharram, PhD, phone number: +33320871033, E-mail: [ghaffar.muhammad@pasteur-](mailto:ghaffar.muhammad@pasteur-lille.fr)
39 [lille.fr](mailto:ghaffar.muhammad@pasteur-lille.fr)

40

41 **Key words:** NOD2, Norovirus, Inflammation, Colitis, Macrophages, Signalling.

42

43 **Data availability statement:** the data that support the findings of this study are available from
44 the corresponding author, GM or MC, upon request on HAL

45

46

47

48 **Abstract.** Over 90% of epidemic nonbacterial gastroenteritis are caused by human Noroviruses
49 (NoV) which are persisting in a substantial subset of people allowing their spread worldwide.
50 It leads to a significant number of endemic cases and up to 70,000 children deaths in developing
51 countries. NoVs are primarily transmitted through the fecal-oral route. To date studies have
52 focused on the influence of the gut microbiota on viral clearance by enteric immunity. **In this**
53 **study, the use of the persistent mouse Norovirus S99 strain (MNoV_S99) allowed us to provide**
54 **evidence that the norovirus-driven exacerbation of colitis severity relied on bacterial sensing**
55 **by nucleotide-binding oligomerization domain 2 (Nod2). Similarly, another persistent**
56 **MNoV_CR6 strain failed to exacerbate colitis severity in Nod2-deficient mice. In parallel, the**
57 **viremia was heightened in these mice in comparison with control animals. Accordingly, a**
58 **reduced level of phosphorylation of Signal Transducer and Activator of Transcription1**
59 **(STAT1) in Nod2-deficient macrophages infected by MNoV_S99 was measured. By contrast,**
60 **STAT1 phosphorylation was increased in wild-type macrophages and associated with an**
61 **induction of NOD2 expression. This in turn enhances myeloid cells response to muramyl**
62 **dipeptide (MDP) resulting in downstream pro-inflammatory cytokine secretion and reduced**
63 **noroviral production. Hence, our results uncover a previously unidentified virus-host-bacterial**
64 **interplay that may represent a novel therapeutic target for treating noroviral origin**
65 **gastroenteritis that may be linked with susceptibility to several common illnesses such as**
66 **Crohn's disease.**

67
68
69
70
71
72
73
74
75
76
77
78

79 **Introduction.** With the development of high throughput sequencing techniques, we are
80 progressively gaining a better knowledge of the composition of the enteric virome (ensemble
81 of gut virus communities)¹. This is of particular importance for unravelling how some enteric
82 viruses can establish persistent infections and the subsequent consequences on health^{2,3}.
83 Amongst enteric viruses yielding pro-inflammatory phenotypes, noroviruses (NoV) are
84 responsible for the majority of non-bacterial gastroenteritis worldwide. **These** single stranded
85 RNA (+) viruses, belonging to the family of *Caliciviridae* have been studied for several years.
86 Until recent progress in cultivation methods of **noroviruses from** genogroups I, II, IV, VIII and
87 IX⁴⁻⁶ **that infect humans** (HuNoVs), mechanistic details were mostly obtained from studies
88 using the mouse norovirus (MNoV)⁷. **Indeed, MNoVs** can be easily produced *in vitro* in
89 macrophages or dendritic cells⁸. Several MNoV strains have been described based on their
90 shedding time in the stool and classified as persistent or acute (non-persistent) strains⁹.
91 **Multiple intracellular pattern recognition receptors (PRR) have been associated with indirect**
92 **noroviral detection, especially during NoV genome replication, when double stranded RNA**
93 **intermediates are generated¹⁰. The Toll like receptor 3 (TLR3) that recognizes any dsRNA in**
94 **the endosomal compartment and the melanoma differentiation associated protein-5 (MDA-5),**
95 **a member of the RIG-I like receptor (RLR) family that recognizes long dsRNA, have been**
96 **shown to participate in the detection of the MNoV_1 strain and its plaque isolate the**
97 **MNoV_CW3¹¹. Amongst the Nod like receptor (NLR) family, Nlrp6 was shown to bind with**
98 **the encephalomyocarditis virus (EMCV), a single strand RNA (+) enteric virus, via the RNA**
99 **helicase Dhx15. Following the formation of these complexes, interferon (IFN) type I and III**
100 **signalling responses are triggered via the recruitment of the mitochondrial antiviral signalling**
101 **(MAVS) protein. Interestingly, this study also showed that, Nlrp6^{-/-} mice infected with**
102 **MNoV_1 had higher viremia, suggesting similar mechanisms of NoV sensing by Nlrp6¹².**
103 **Another member of the NLR family, the nucleotide-binding oligomerization domain 2 (NOD2)**

104 mostly known as a sensor of muropeptides from Gram positive and negative bacteria¹³, was
105 also shown to directly bind with the genome (ssRNA-) of the respiratory syncytial virus (RSV)
106 to induce antiviral responses¹⁴. The recruitment of MAVS by NOD2 was needed to activate the
107 interferon-regulatory factor 3 (IRF3) dependent signalling and provoke IFN- β production. In
108 the same line, NOD2 dependent signalling was shown to potentiate gut inflammation and
109 increase lethality in an *E. Coli* and MNoV_1 co-infection mouse model¹⁵.

110 Another molecular player that is essential to activate antiviral signalling is the cytosolic protein
111 signal transducer and activator of transcription 1 (STAT1). MNoV_1 infections were shown to
112 be lethal in STAT1 knock-out mice¹⁶. Furthermore, STAT1 dependent interferon responses
113 were shown to limit MNoV_1 replication and dissemination *in vivo*¹⁷.

114 Owing to the variety of circulating NoV strains, strain-dependent effects are expected to occur
115 and should be studied more in details. Even a single amino acid change in the NS1/2 viral
116 protein is sufficient to switch the acute MNoV_CW3 strain to a persistent state¹⁸, showing the
117 high degree of adaptability of NoV genomes and hence their versatility to counteract host
118 defence mechanisms. Type III interferon (IFN- λ) response has been shown to control the *in*
119 *vivo* propagation of the persistent MNoV_CR6 strain¹⁹, while type I and II interferons mediate
120 innate immune responses against acute MNoV infections^{16,20}.

121 Interestingly, Cadwell and colleagues have demonstrated how infection with the MNoV
122 persistent strain CR6 rendered *Atg16l1^{HM}* mice more susceptible to dextran sodium sulphate
123 (DSS)-induced colitis²¹. Interestingly, NOD2's interaction with ATG16L1 was shown to
124 regulate the autophagy clearance of pathogenic bacteria²². Indeed, improper interaction with
125 muropeptides and other metabolites from the gut microbiota leads to intestinal inflammation²³
126 and loss-of-function point mutations of either *NOD2* or *ATG16L1* predispose humans to
127 Crohn's disease^{24,25}. Insights into the mechanisms of how NOD2 signaling is regulated upon

128 noroviral infection and whether it may subsequently modulate colitis susceptibility remained to
129 be assessed.

130 In this study, we have investigated the underlying mechanism of the pathogenesis of two
131 persistent MNoV strains, namely S99 (*Berlin*)²⁶ and CR6. MNoV_S99 dependent inflammatory
132 response to DSS was compared in WT and *Nod2*^{-/-} mice. Similarly, the consequences of
133 infections with MNoV_CR6 on disease risk were assessed in WT, *Nod2*^{-/-} and *Atg1611*^{HM} mice.
134 Nod2-dependent pro-inflammatory signalling pathways activation were further examined in
135 response to MNoV_S99 infection in myeloid cells to determine how this in turn may affect
136 viral production.

137

138

139 **Results.**

140 **MNoV_S99 exacerbates the DSS-induced inflammation**

141 Since MNoV_S99 is a natural strain commonly found in animal facilities that is able to establish
142 persistent infections²⁶, we assessed MNoV_S99's implication in the vulnerability to
143 exacerbated inflammatory responses of the intestinal mucosa. Hence, we examined
144 MNoV_S99's impact in a widely used chemically-induced colitis model that is induced upon
145 administration of Dextran Sodium Sulfate (DSS). Specifically, C57BL/6J mice were first
146 infected with a single dose of 10⁷ TCID₅₀PFU of MNoV_S99 or mock-treated with PBS. One
147 week later, drinking water was replaced with either a 3% DSS or 5% DSS solution for a period
148 of seven consecutive days (Fig. 1A). Body weight-loss was monitored on a daily basis together
149 with signs of diarrhea and rectal bleeding. With both concentrations of DSS, the pre-treatment
150 with MNoV_S99 had induced a more significant body weight loss (purple and orange curves
151 Fig. 1B and C). After 7 days of DSS treatment, mice were euthanized. Histological analysis of
152 colon sections revealed an increased infiltration of inflammatory cells and epithelial damage in

153 infected mice treated with DSS when compared to similarly challenged animals that were not
154 infected (Fig. 1D). Next, we quantified the muscle thickness from these colon sections. An
155 increased thickness was measured in mice treated with the virus in presence of both 3 and 5%
156 DSS in comparison with Mock-treated control mice (Fig. 1E). Similarly, histological scoring
157 of the haematoxylin and eosin (H&E) stained colonic sections expectedly showed significantly
158 more severity in mice treated with MNoV_S99 + 3% or 5% DSS than DSS alone (Fig. 1F).
159 Upon mice sacrifice, resected colons were measured. A significantly reduced length was
160 obtained in mice infected with MNoV_S99 and treated with 5% DSS in comparison with non-
161 infected control animals (PBS) (Fig. 1G). The increased level of colitis was also evidenced by
162 a significantly augmented secretion of the pro-inflammatory cytokine interleukin-6 (IL-6) in
163 the supernatants of over-night *in vitro* cultured colon explants from MNoV_S99 infected + 5%
164 DSS treated mice versus those from DSS only mice (Fig. 1H). Taken together, these data clearly
165 show a much worse inflammation state in mice infected with MNoV_S99 in our chemically
166 induced colitis model.

167

168 **MNoV_S99 associated inflammation is abrogated in *Nod2*^{-/-} mice**

169 In cells from the myeloid lineage, NOD2 was shown to participate in the sensing of *Citrobacter*
170 *rodentium* and of commensal bacteria that are translocating in response to chemically-induced
171 epithelial injury²⁷. To determine whether NOD2 is also implicated in the immunopathology of
172 MNoV in our preclinical model of colitis, we compared the severity of DSS-induced colitis in
173 the presence of MNoV_S99 or not between WT and *Nod2*-deficient mice. In contrast to what
174 was observed in WT mice (Fig. 2A), the sensitizing effect of the virus on the daily weight-loss
175 was absent upon MNoV_S99 infection of *Nod2*^{-/-} mice (Fig. 2B). These data suggest that the
176 pro-inflammatory effect of MNoV_S99 observed in WT mice is a consequence of a loss of
177 tolerance to bacterial MDP. Indeed, DSS induces an abrasion of the epithelial barrier allowing

178 commensal bacteria to cross the mucosa and unleash a pro-inflammatory response from *Nod2*
179 expressing cells. This was further confirmed after mice were autopsied. Colon tissue sections
180 staining confirmed the decreased levels of colonic inflammation from MNoV_S99 infected
181 *Nod2*^{-/-} vs WT mice (Fig. 2C). In agreement, muscle thickness quantification from these colon
182 sections showed significantly increased thickness in MNoV_S99-infected WT mice under 3%
183 DSS treatment vs 3% DSS alone (Fig. 2D). While in *Nod2*^{-/-} mice subjected to similar
184 conditions, the excess of inflammation caused by the viral infection was lost. Consequently, the
185 variations of colon length measurements that were induced upon MNoV_S99 infection were
186 absent in *Nod2*^{-/-} mice when compared to WT infected mice (Fig. S1A). Similarly, differences
187 in histological scores measured from MNoV_S99-infected WT mice vs DSS alone were also
188 lost in *Nod2*^{-/-} infected mice (Fig. S1B). **And a clear trend was observed regarding the increased**
189 **levels of secretion of Tumour necrosis factor α (TNF α) in the supernatants of *in vitro* cultured**
190 **colon explants from WT mice infected with MNoV_S99 and treated with 3% DSS vs those**
191 **with DSS only. This effect was absent in the supernatants from *Nod2*^{-/-} mice infected and treated**
192 **similarly (Fig. S1C).**

193 Overall, these data show the importance of bacterial sensing by NOD2 and the excessive
194 inflammatory response measured in the presence of MNoV_S99 in our DSS-induced colitis
195 mouse model.

196

197 **Mouse noroviruses infections triggers NOD2-dependent pro-inflammatory signalling**

198 Mouse noroviruses are known to have a tropism for the myeloid cell lineages, namely
199 macrophages and dendritic cells. Recently it was shown that Tuft cells belonging to the gut
200 epithelial cellular lineages, that possess the CD300lf MNoV receptor can also be targeted by
201 the MNoV_CR6 strain²⁸.

202 Making use of the GFP-Nod2 reporter mice line, we first examined in which cellular lineages
203 Nod2 is expressed. We failed to observe GFP-Nod2 expression in epithelial cells, while plenty
204 of signal was detectable in the bulk of the cells **below** the lamina propria where myeloid cells
205 are located (Fig. 3A). Hence, our investigations regarding NOD2 expression variations in
206 response to MNoV_S99 infection focused on macrophages, monocytes and dendritic cells in
207 our *in vitro* cellular models.

208 Interferon production being one of the most common response to the intracellular presence of
209 RNA genomes of foreign origin, we examined if the STAT1 signalling pathway that lays
210 upstream of ATG1611-mediated interferon production was activated in response to murine
211 norovirus infection.

212 To this end, bone marrow derived macrophages (BMDM) from WT mice were infected with
213 several MNoV strains at a multiplicity of infection (Moi) of 1, for 1h and pSTAT1 levels of
214 expression from cell lysates were measured by western blot (Fig. 3B). In contrast to the non-
215 persistent strain MNoV_CW3 that caused a striking increase in pSTAT1 level, the persistent
216 strains S99 and CR6 infections induced a much milder STAT1 signalling pathway activation.
217 The CW1 strain was associated with the lowest level of activation. Since MNoV_S99 is a
218 natural strain commonly found in animal facilities that is able to establish persistent infections,
219 we further analysed the mechanistic details behind its infection in our cellular models.

220 Using the macrophage cell-line Raw264.7, we confirmed that MNoV_S99 is able to induce
221 phosphorylation of STAT1 (Tyrosine 701) at different times at Moi 1 (Fig. S3). pSTAT1 was
222 detectable as early as 15 minutes post-infection and its expression further increased at 30 min
223 and 1h, while total STAT1 was detectable in control non-infected cells and its expression only
224 slightly increased at later time-points. In addition to the STAT1 activation through the Janus
225 kinases JAK1 and Tyk2, we also examined the status of NFκB activation, another pro-
226 inflammatory signalling pathway. For this purpose, pIκBα levels were quantified from infected

227 cell lysates. Despite basal low-level activation in mock-infected cells, pI κ B α intensity increased
228 slightly at 30 min and 1h post-infection. However, no significant increase was measured. When
229 checking PI3K-AKT or the MAPK-ERK signalling axes **in the same time frame**, MNoV_S99
230 failed to induce any activation of these signalling pathways (**Fig. S2**). Next, we analyzed the
231 response of BMDM derived from WT or *Nod2*^{-/-} mice that were infected with increasing doses
232 of MNoV_S99 for 30 or 60 minutes (Fig. 3C). STAT1 activation increased over the course of
233 the acute infection in cells derived from WT mice. In contrast, the levels of pSTAT1 were
234 barely detectable in *Nod2*^{-/-} cells at Moi 1. However, at a higher dose (Moi 5), Nod2-dependent
235 STAT1 activation was only observable at the 30 minutes time point. At 60 minutes post-
236 infection, the decrease in pSTAT1 levels in response to MNoV_S99 infection was not
237 significant anymore when compared with WT cells.

238 Next, we examined if Stat1 activation was detectable after prolonged times of infection. Indeed,
239 we measured significant differences in pStat1 expression levels between WT and *Nod2*^{-/-}
240 MNoV_S99-infected cells 24h post-infection at Moi 0.1 (Fig. 3D).

241 To examine whether the Mitochondrial antiviral signalling (MAVS) adaptor protein is required
242 for sensing MNoV_S99, BMDM derived from *Mavs*-deficient mice were compared to WT
243 cells. Interestingly, the higher pStat1 levels measured in WT cells (Moi 0.1, 1h) were
244 significantly decreased in cells derived from *Mavs*^{-/-} cells (Fig. 3E).

245 Altogether, these data show a mild but significant activation of pro-inflammatory signalling
246 pathways following MNoV_S99 infection in our *in vitro* cellular models. These signalling
247 responses can be at least partially abrogated in the absence of MAVS and NOD2.

248

249 **Lower levels of inflammation in *Nod2*^{-/-} mice benefit noroviral propagation**

250 **MNoV_CR6 infection in DSS-induced colitis was previously shown to promote inflammation**
251 **in a functional Atg1611 dependent manner²¹. Using this viral strain, we checked how loss of**

252 *Nod2* influenced resolution of inflammation in response to 3% DSS treatment. As shown with
253 the S99 strain, the significantly increased inflammation levels measured by colon wall muscle
254 thickening were abrogated in *Nod2*^{-/-} mice (Fig. 4A). However, a CR6 strain-specific effect can
255 be observed with these experiments since no significantly increased inflammation was
256 measured in WT mice as opposed to *Atg16l1* hypomorph mice.

257 Next, we examined the impact of the pro-inflammatory signalling activation on viral
258 propagation in these mice. In the absence of DSS induced inflammation no significant
259 differences could be found when comparing the viral load in the stool of WT, *Atg16l1*^{HM} or
260 *Nod2*^{-/-} mice (Fig. 4B). But, when gut epithelium tissue sections were assessed from mice
261 treated with DSS, the measured viral load was significantly increased in ileum and colon of
262 *Nod2*^{-/-} mice in comparison with inflamed tissues of *Atg16l1*^{HM} mice (Fig. 4C).

263 We have also analyzed the viral replication in BMDM derived from WT or *Nod2*^{-/-} mice
264 infected *in vitro* with MNoV_S99 (Moi 0.1 for 24h). In that case a slight but significant increase
265 in the number of viral genomes was measured from *Nod2*^{-/-} derived cultures (Fig. 4D).

266 Hence, albeit some strain effect differences between CR6 and S99, the lower levels of
267 inflammation found in *Nod2*^{-/-} mice seems to favour a higher propagation of these two persistent
268 strains.

269

270 **MNoV_S99 persistence is decreased with loss of tolerance to Bacterial MDP**

271 To further explore the mechanisms behind the excessive inflammatory response associated with
272 noroviral infections we examined *Nod2* expression levels by RT-qPCR. Interestingly, they were
273 significantly increased in response to MNoV_S99 infection in Raw264.7 cells or BMDM
274 derived from WT mice (Fig. 5A and 5B).

275 This increased *Nod2* expression following norovirus infection could explain the viral-induced
276 pathogenesis that we observed in our colitis models. Indeed, with augmented NOD2 levels the

277 inflammatory response of myeloid cells from the lamina propria should spike up when suddenly
278 interacting with intestinal commensal bacteria following DSS-induced epithelial abrasion.
279 To gain a better understanding of how these two stimuli work in tandem, we examined in our
280 *in vitro* cellular models, Stat1 and I κ B α signalling pathways activation in response to
281 MNoV_S99 infection followed by MDP treatment. As previously shown with BMDM or
282 Raw264.7 cells, MNoV_S99 infection did also induce Stat1 activation in monocytes isolated
283 from WT mice (Fig. 5C and 5D, MNoV_S99+, MDP- condition). Similarly, I κ B α was not
284 activated by the viral infection alone. Though, relatively high basal levels were already
285 detectable in mock-infected cells. As expected the treatment with the peptidoglycan MDP alone
286 triggered potent I κ B α activation without activating Stat1 (Fig. 5C, MNoV_S99-, MDP+
287 condition). Interestingly, while I κ B α activation by single MNoV_S99 infection was not
288 achievable, MNoV_S99 infection followed by secondary MDP treatment was associated with
289 both pathways' moderate but significant activation (Fig. 5D, MNoV_S99+, MDP+ vs mock
290 treated cells). In the same line of investigation, we noticed a significantly augmented pro-
291 inflammatory cytokine TNF α response to MDP in dendritic cells that were first primed with
292 Noroviral RNA (Fig. 5E). Next, we compared WT and *Nod2*^{-/-} derived BMDM cultures' TNF α
293 response to MNoV_S99 infection followed by MDP treatment. TNF α levels were increased
294 with increasing doses of virus in WT cells, while they remained undetectable (Moi 0.1) or much
295 lower (Moi 1) in *Nod2*^{-/-} cells (Fig. 5F). Consequently, when noroviral replication levels were
296 compared between Raw264.7 cells only infected with MNoV_S99 and those infected + MDP
297 treated, viral titers measured in supernatants showed significantly decreased yields in the latter
298 case (Fig. 5G).

299 Overall, these *in vitro* data fit nicely with our *in vivo* models. The increased *Nod2* transcription
300 levels following noroviral infection in turn favours excessive inflammatory signalling pathways
301 activation in the presence of bacterial MDP, leading ultimately to a limitation in the viral

302 propagation. Hence the lower inflammation in *Nod2*^{-/-} mice is associated with increased
303 propagation of MNoV_S99 and MNoV_CR6 strains.

304 **Discussion**

305 The breach in gut flora homeostasis termed dysbiosis is becoming central in the onset of chronic
306 inflammatory bowel disease, such as Crohn's disease^{29,30}. With the development of molecular
307 biology techniques, alterations in the virome relevant to disease pathogenesis are thoroughly
308 under investigation². The cytosolic sensor NOD2 is very well known for its pathogen associated
309 molecular pattern recognition activity against bacteria¹³, and recently it appears it can also
310 participate in detection of certain viruses¹⁴. Hence, the combination of genetic susceptibility
311 factors and opportunistic viral infections could be one of the triggers of CD³¹. Using pro-
312 inflammatory signalling activation downstream of NOD2 as a read-out, we have analysed if
313 NOD2 can also participate in MNoV detection. All our *in vitro* experiments with monocytic
314 lineage derived primary cells (e.g. BMDM, BMDC and BM) and cell line (e.g. Raw264.7)
315 infected with different MNoV strains showed activation of the STAT1 signalling pathway
316 implicated in the pro-inflammatory IFN response. By contrast, these responses were abrogated
317 in *Nod2*^{-/-} and *Mavs*^{-/-} mice derived BMDM.

318 Amongst enteric viruses commonly found in the microbiota, the Norovirus is considered as a
319 good candidate in the hypothesis of an environmental-driver in genetically susceptible hosts at
320 the origin of Crohn's disease onset. MNoV_CR6 strain was shown to induce colitis in
321 *Atg1611*^{HM} mice presenting defective autophagy in a DSS colitis model²¹.

322 Several PRR are implicated in viral sensing. MDA-5 and TLR3 have been shown to participate
323 in detection of either MNoV_1 or CW3¹¹. These are both strains which do not persist *in vivo*,
324 contrary to the S99 (*Berlin*)²⁶ and CR6 that were used in our study.

325 Our *in vivo* data show significantly exacerbated inflammation when applying either 3% or 5%
326 DSS colitis protocol to WT or *Atg1611*^{HM} mice. The excessive MNoV-S99 or MNoV_CR6

327 associated inflammatory response was abrogated in *Nod2*^{-/-} mice or in BMDM derived from
328 these mice showing NOD2's implication in the pathogenesis and the viral sensing respectively.
329 Hence, NOD2 dependent signalling adds a layer of regulation in viral sensing and finetunes the
330 immunopathology levels caused by the infection. While in our Norovirus + DSS model
331 knocking-down NOD2 prevents gut inflammation, it has the opposite effect with Influenza A
332 virus (IAV) infection in the lung of *Nod2*^{-/-} or *Ripk2*^{-/-} mice³². Indeed, the NOD2-RIPK2
333 signalling axe has been shown to downmodulate the NLRP3 dependent mitophagy activation
334 and the associated inflammatory response in the lung tissue of infected mice.

335 Noroviruses propagation or prolonged persistence is tightly regulated by the interplay between
336 several signalling pathways. MNoV_1 replication was shown to be inhibited in macrophages
337 following LPS mediated NF- κ B activation that in turn triggers IFN- β dependent JAK-STAT
338 antiviral activity³³. Interestingly, in our cellular models, in addition to the phosphorylation of
339 STAT1 that we observed when cells were infected with MNoV_S99, *Nod2* expression levels
340 were also increased. Consequently, the subsequent treatment with MDP induced an increased
341 Nf κ B signalling pathway via I κ B α activation. The sequential activation of these two pro-
342 inflammatory signalling pathways resulted in the inhibition of the MNoV_S99 propagation on
343 one hand and the augmented production of the pro-inflammatory cytokine TNF α on the other
344 hand. Hence, the aggravated inflammatory pathology we observed in our DSS colitis model
345 can be explained by this NOD2-dependent signalling loop in MNoV_S99 or MNoV_CR6
346 infected mice. Similarly, *in vitro* the signalling and cytokine responses were NOD2 dependent
347 since they were only observed in cultures derived from WT but not in *Nod2*^{-/-} mice, at least at
348 a lower dose (Moi 0.1) of infection. At higher doses, NOD2-independent alternative
349 mechanisms seem to be active to promote Stat1 activation and TNF α production, but still at a
350 lesser level than in WT cells.

351 In conclusion, our study shows a NOD2 dependent mechanism that prevents low level
352 propagation of the persistent MNoV_S99 and MNoV_CR6 strains. When the noroviral
353 infection is coupled with digestive tract injury a positive signalling loop generates a potent pro-
354 inflammatory response that limits viral propagation.

355

356

357

358 **Methods:**

359 Unless otherwise indicated, all media and reagents were purchased from ThermoFischer
360 Scientific.

361

362 **Colitis mouse model and viral infection**

363 All animal experiments were approved by the local ethical committee n° CEEA-
364 2016030717519903. Age and gender related *Nod2*^{-/-} and wild type littermates C57BL/6J mice
365 (CDTA, Orléans, France) were housed 4-6 per cage, under strict pathogens-free environment.
366 Mice were gavaged with 10⁷ TCID₅₀PFU/mL of MNoV_S99 diluted in 200µl PBS or mock
367 treated with PBS only. 7 days post-infection, drinking water was substituted with a 3-5%
368 dextran sodium sulphate (DSS) (35,000-40,000 MW; TdB Consultancy) solution replaced
369 every 2 days for a total duration of 7 days. **3% DSS colitis experiments with MNoV_CR6 were**
370 **conducted as previously described in²¹.**

371 **Cells and virus**

372 Mouse leukemic monocyte macrophage cell line RAW264.7 were purchased from ECCAC
373 (Sigma-Aldrich) and maintained in Dulbecco's modified Eagle's medium (DMEM),
374 supplemented with 10% (v/v) foetal bovine serum, 1% penicillin/streptomycin and 1% sodium
375 pyruvate.

376 Bone marrow derived macrophages (BMDM) were isolated from femurs of wild-type, *Nod2*^{-/-}
377 or *Mavs*^{-/-} mice of C57BL/6J background³⁴. Briefly, bone marrow cells were flushed out of the
378 bones, red blood cells were lysed using a 160mM NH₄CL and 170mM Tris solution for 5
379 minutes at RT. 3 to 6.10⁶ viable cells were plated in non-cell-culture-treated petri dishes and
380 grown for 5-7 days in Iscove's modified Dulbecco's medium (IMDM), supplemented with 10%
381 foetal bovine serum, 1% penicillin/streptomycin, 1% non-essential amino acid, 1% sodium
382 pyruvate, 1% glutamine, and 20% (v/v) conditioned-media from L929 cells.

383 Bone marrow derived dendritic cells were isolated similarly as BMDM cells. Then, 2.10⁶ viable
384 cells were plated in non-cell-culture-treated petri dishes and grown for 7 days in RPMI 1640,
385 supplemented with 10% FBS, 1% P/S, 1% L-glutamine, 1% HEPES and 20% (v/v) conditioned-
386 media from J558 cell line producing murine granulocyte monocyte colony stimulating factor
387 (GM-CSF).

388 Monocytes were isolated from bone marrow cells by using the mouse Monocyte Isolation Kit
389 (Miltenyi Biotec) and a QuadroMACS separator.

390 The MNoV-S99 strain (GenBank accession no. DQ911368) was provided by Prof. P. Maris
391 from ANSES Fougères Laboratory (France) and was propagated in RAW 264.7 cells. **MNoV-**
392 **CR6 concentrated stocks were prepared as described in³⁵. Briefly, supernatant from 293T cells**
393 **transfected with a plasmid containing the viral genome was applied to RAW264.7 cells to**
394 **amplify virus production, and virions were concentrated by ultracentrifugation and**
395 **resuspension in endotoxin-free PBS. Concentration of stocks was determined by plaque assay.**

396 For in vitro infection experiments, 3-5.10⁵ viable cells were seeded in 6 wells plates. The next
397 day, just before viral infection, cells were counted from 1 well to determine precisely the
398 multiplicity of infection (Moi). In the remaining wells medium was removed and replaced with
399 variable quantities of MNoV_S99 from a common viral stock in a final volume of 1 mL fresh

400 medium per well. Mock treated cells were incubated in parallel with matching quantities of
401 culture media from non-infected cells that was generated at the same time as viral stocks.
402 At various time-points after infection, supernatant was removed and cells were washed once
403 with PBS, before lysis in RIPA buffer for WB analysis or RLT buffer for total RNA extraction
404 (RNAeasy kit, Quiagen) for RT-qPCR experiments.

405

406 **Immunohistochemistry, ELISA, Western Blot, RT-qPCR and Titration**

407 For immunohistochemistry analysis, formalin-fixed colon samples were embedded in paraffin.
408 5µm sections were stained with H&E. Slides were imaged with an AxioPlan 2 (Zeiss)
409 microscope and blindly scored for inflammation severity by two investigators as previously
410 described³⁷.

411 For ELISA analysis, briefly 1cm colon samples were recovered from mice, luminal content was
412 flushed with PBS, samples were cut opened and resuspended over-night in 250µl DMEM
413 supplemented with 1% P/S in 24 wells plate at 37°C. The following day, supernatants were
414 collected and stored at -80°C before cytokine measurement. TNFα and Interleukin-6 proteins
415 levels were measured specifically using pre-coated 96 wells ELISA plates (R&D System)
416 following manufacturers indications.

417 For TNFα ELISA from BMDC, 5.10⁵ cells were plated in 24 wells plate and treated with
418 MNoV_S99's ssRNA (extracted with RNeasy Quiagen kit) **with Lipofectamine 2000**¹⁴ ± MDP
419 or MDP-DD (Invivogen) over-night and supernatants were measured for TNFα levels.

420 For TNFα ELISA from BMDM, 2.10⁵ cells were plated in 96 wells plate infected with
421 MNoV_S99 (Moi 0.1 or 1) for 6h prior to MDP treatment (10ug/mL) over-night and
422 supernatants were measured for TNFα levels.

423 For western blot analysis, total proteins from cell lysates were quantified by BCA protein assay
424 kit (Pierce), equalized amounts of proteins (10-20µg) were resolved by 4-15% gradient SDS-

425 PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked in 0,05%
426 PBS-Tween, 5% skimmed milk solution, before incubation subsequently with primary and
427 secondary antibodies diluted (see Table 1) in blocking solution. Following secondary antibodies
428 incubations, signals of interest were detected using a chemiluminescence reader
429 (ImageQuant™ Las 4000, GE Healthcare Life Sciences), images were processed and band ROI
430 were quantified with Image J software (NCBI). Mean band intensities \pm SD of protein of
431 interest were normalized to β -actin. Relative values to control mock-infected conditions were
432 compared between different experiments.

433 For *Nod2* quantification from MNoV_S99 infected BMDM or RAW264.7 cells, total RNA
434 extraction was performed using the RNeasy Mini Kit (Qiagen). One μ g of RNA was reversed
435 transcribed in the presence of 2.5mM of oligo-dT using the Reverse Transcriptor kit (Roche)
436 following the manufacturer's instructions. 75ng of cDNAs were amplified using Q5 High-
437 Fidelity 2X Master Mix (New England BioLabs). Primers used in PCR amplification are
438 available upon request.

439 *Actb* was used as an internal reference gene in order to normalize the transcript levels. Relative
440 mRNA levels ($2^{-\Delta\Delta Ct}$) were determined by comparing (a) the PCR cycle thresholds (Ct) for
441 *Nod2* and *Actb* (ΔCt) and (b) ΔCt values for treated and control groups ($\Delta\Delta Ct$).

442 MNoV_S99 load was determined by measuring MNoV genome copy numbers by RT-qPCR
443 analysis as previously described³⁶. Briefly, total RNA was extracted from BMDM cell cultures
444 using the RNeasy Mini Kit (Qiagen). 5 μ L of RNA were used per reaction of RT-qPCR. Viral
445 genome levels were determined using the Takyon™Dry No Rox One-Step RT Probe
446 Mastermix (Eurogentec). Viral genomes were specifically amplified using the
447 Fwd_5'GTGCGCAACACAGAGAAAACG3' and Rev_5'CGGGCTGAGCTTCCTGC3'
448 primers that target MNoV ORF1 region combined to a TaqMan probe using the Stratagene
449 Mx3005P (Agilent Technologies). The quantification of viral genome copies was obtained

450 using a standard curve with serial dilutions of the plasmid pMNoV1 corresponding to the full
451 genome of MNoV1 (Dr Christiane Wobus, University of Michigan, USA). **Viral load for**
452 **MNoV_CR6 strain was determined by measuring genome copy numbers by RT-qPCR analysis**
453 **as previously described in²¹.**

454 **The net production of MNoV_S99 was determined using the TCID₅₀ method as described in³⁶.**
455 **Briefly, Raw264.7 cells were infected at Moi 1 with MNoV_S99 for 2h, before adding MDP**
456 **(100ng/mL) or not in the supernatant for 24h. Titers (n = 3) were obtained from each**
457 **supernatant. The net production is calculated by normalizing the amount of viruses produced**
458 **with the amount of viruses used for the infection.**

459

460 ***NOD2^{GFP}* immunohistochemistry imaging**

461 *NOD2^{GFP}* mice³⁸ in the C57BL/6 background were maintained at the Institut Pasteur Central
462 Animal facility. We used heterozygous *NOD2^{GFP}* mice since the presence of one functional
463 copy of *NOD2* ensures that physiological responses dependent on functional *NOD2* are not
464 impaired. Heterozygous *NOD2^{GFP}* female mice (8-12 weeks of age) were sacrificed and several
465 centimeters of the distal ileum were removed, opened longitudinally and washed in PBS. The
466 tissue was spread flat over a 4% w/v LMP agarose (Merck) pad and fixed with 4% v/v
467 paraformaldehyde (VWR). The ileal tissue was then embedded in a 4% LMP agarose block and
468 cut into 200µm-thick sections using a Microm HM 650 V Vibration microtome.

469 For staining, tissues were blocked, permeabilized and marked with an anti-GFP (rabbit
470 polyclonal antibody A-11122) primary antibody and secondary Alexa Fluor 488 goat anti-
471 rabbit antibody. Tissues sections were counter stained with DAPI (1µg/mL, BD Biosciences)
472 and Phalloidin- iFluor 647 (1:200 dilution, Abcam and mounted using ProLong Gold Antifade
473 reagent. Confocal acquisitions were performed using a Leica HyD SP5 confocal microscope.
474 Image analysis was performed using Icy version 2.4.2.0³⁹.

476 **References:**

- 477 1. Cadwell, K. Expanding the role of the virome: commensalism in the gut. *J. Virol.* **89**,
478 1951–1953 (2015).
- 479 2. Norman, J. M. *et al.* Disease-specific alterations in the enteric virome in inflammatory
480 bowel disease. *Cell* **160**, 447–460 (2015).
- 481 3. Pfeiffer, J. K. & Virgin, H. W. Viral immunity. Transkingdom control of viral
482 infection and immunity in the mammalian intestine. *Science* **351**, aad5872 (2016).
- 483 4. Ettayebi, K. *et al.* Replication of human noroviruses in stem cell-derived human
484 enteroids. *Science* **353**, 1387–1393 (2016).
- 485 5. Estes, M. K. *et al.* Human Norovirus Cultivation in Nontransformed Stem Cell-
486 Derived Human Intestinal Enteroid Cultures: Success and Challenges. *Viruses* **11**, E638
487 (2019).
- 488 6. Ludwig-Begall, L. F., Mauroy, A. & Thiry, E. Noroviruses-The State of the Art,
489 Nearly Fifty Years after Their Initial Discovery. *Viruses* **13**, 1541 (2021).
- 490 7. Newman, K. L. & Leon, J. S. Norovirus immunology: Of mice and mechanisms. *Eur.*
491 *J. Immunol.* **45**, 2742–2757 (2015).
- 492 8. Wobus, C. E. *et al.* Replication of Norovirus in cell culture reveals a tropism for
493 dendritic cells and macrophages. *PLoS Biol.* **2**, e432 (2004).
- 494 9. Thackray, L. B. *et al.* Murine noroviruses comprising a single genogroup exhibit
495 biological diversity despite limited sequence divergence. *J. Virol.* **81**, 10460–10473 (2007).
- 496 10. Thorne, L. G. & Goodfellow, I. G. Norovirus gene expression and replication. *J. Gen.*
497 *Virol.* **95**, 278–291 (2014).
- 498 11. McCartney, S. A. *et al.* MDA-5 recognition of a murine norovirus. *PLoS Pathog.* **4**,
499 e1000108 (2008).
- 500 12. Wang, P. *et al.* Nlrp6 regulates intestinal antiviral innate immunity. *Science* **350**, 826–
501 830 (2015).
- 502 13. Chamailard, M., Girardin, S. E., Viala, J. & Philpott, D. J. Nods, Nalps and Naip:
503 intracellular regulators of bacterial-induced inflammation. *Cell. Microbiol.* **5**, 581–592
504 (2003).
- 505 14. Sabbah, A. *et al.* Activation of innate immune antiviral responses by Nod2. *Nat.*
506 *Immunol.* **10**, 1073–1080 (2009).
- 507 15. Kim, Y.-G. *et al.* Viral infection augments Nod1/2 signaling to potentiate lethality
508 associated with secondary bacterial infections. *Cell Host Microbe* **9**, 496–507 (2011).
- 509 16. Karst, S. M., Wobus, C. E., Lay, M., Davidson, J. & Virgin, H. W. STAT1-dependent
510 innate immunity to a Norwalk-like virus. *Science* **299**, 1575–1578 (2003).
- 511 17. Mumphrey, S. M. *et al.* Murine norovirus 1 infection is associated with
512 histopathological changes in immunocompetent hosts, but clinical disease is prevented by
513 STAT1-dependent interferon responses. *J. Virol.* **81**, 3251–3263 (2007).
- 514 18. Nice, T. J., Strong, D. W., McCune, B. T., Pohl, C. S. & Virgin, H. W. A single-
515 amino-acid change in murine norovirus NS1/2 is sufficient for colonic tropism and
516 persistence. *J. Virol.* **87**, 327–334 (2013).
- 517 19. Nice, T. J. *et al.* Interferon- λ cures persistent murine norovirus infection in the
518 absence of adaptive immunity. *Science* **347**, 269–273 (2015).
- 519 20. Hwang, S. *et al.* Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein
520 complex in antiviral activity of interferon gamma. *Cell Host Microbe* **11**, 397–409 (2012).
- 521 21. Cadwell, K. *et al.* Virus-plus-susceptibility gene interaction determines Crohn's
522 disease gene Atg16L1 phenotypes in intestine. *Cell* **141**, 1135–1145 (2010).

- 523 22. Travassos, L. H. *et al.* Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the
524 plasma membrane at the site of bacterial entry. *Nat. Immunol.* **11**, 55–62 (2010).
- 525 23. Maloy, K. J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory
526 bowel disease. *Nature* **474**, 298–306 (2011).
- 527 24. Hugot, J. P. *et al.* Association of NOD2 leucine-rich repeat variants with susceptibility
528 to Crohn’s disease. *Nature* **411**, 599–603 (2001).
- 529 25. Hampe, J. *et al.* A genome-wide association scan of nonsynonymous SNPs identifies a
530 susceptibility variant for Crohn disease in ATG16L1. *Nat. Genet.* **39**, 207–211 (2007).
- 531 26. Niendorf, S., Klemm, U., Mas Marques, A., Bock, C.-T. & Höhne, M. Infection with
532 the Persistent Murine Norovirus Strain MNV-S99 Suppresses IFN-Beta Release and
533 Activation of Stat1 In Vitro. *PloS One* **11**, e0156898 (2016).
- 534 27. Hrdý, J. *et al.* Lactobacillus reuteri 5454 and Bifidobacterium animalis ssp. lactis 5764
535 improve colitis while differentially impacting dendritic cells maturation and antimicrobial
536 responses. *Sci. Rep.* **10**, 5345 (2020).
- 537 28. Wilen, C. B. *et al.* Tropism for tuft cells determines immune promotion of norovirus
538 pathogenesis. *Science* **360**, 204–208 (2018).
- 539 29. Hold, G. L. *et al.* Role of the gut microbiota in inflammatory bowel disease
540 pathogenesis: what have we learnt in the past 10 years? *World J. Gastroenterol.* **20**, 1192–
541 1210 (2014).
- 542 30. Kim, D. H. & Cheon, J. H. Pathogenesis of Inflammatory Bowel Disease and Recent
543 Advances in Biologic Therapies. *Immune Netw.* **17**, 25–40 (2017).
- 544 31. Simmons, A. Crohn’s disease: Genes, viruses and microbes. *Nature* **466**, 699–700
545 (2010).
- 546 32. Lupfer, C. *et al.* Receptor interacting protein kinase 2-mediated mitophagy regulates
547 inflammasome activation during virus infection. *Nat. Immunol.* **14**, 480–488 (2013).
- 548 33. Yu, P., Li, Y., Wang, Y., Peppelenbosch, M. P. & Pan, Q. Lipopolysaccharide restricts
549 murine norovirus infection in macrophages mainly through NF- κ B and JAK-STAT signaling
550 pathway. *Virology* **546**, 109–121 (2020).
- 551 34. Michallet, M.-C. *et al.* TRADD protein is an essential component of the RIG-like
552 helicase antiviral pathway. *Immunity* **28**, 651–661 (2008).
- 553 35. Kernbauer, E., Ding, Y. & Cadwell, K. An enteric virus can replace the beneficial
554 function of commensal bacteria. *Nature* **516**, 94–98 (2014).
- 555 36. Hwang, S. *et al.* Murine norovirus: propagation, quantification, and genetic
556 manipulation. *Curr. Protoc. Microbiol.* **33**, 15K.2.1-61 (2014).
- 557 37. Wirtz, S. *et al.* Chemically induced mouse models of acute and chronic intestinal
558 inflammation. *Nat. Protoc.* **12**, 1295–1309 (2017).
- 559 38. Barreau, F. *et al.* CARD15/NOD2 is required for Peyer’s patches homeostasis in mice.
560 *PloS One* **2**, e523 (2007).
- 561 39. de Chaumont, F. *et al.* Icy: an open bioimage informatics platform for extended
562 reproducible research. *Nat. Methods* **9**, 690–696 (2012).
- 563

564 **Acknowledgments:**

565 For the *NOD^{GFP}* tissue imaging, we thank the UTechS PBI, a member of the France–
566 BioImaging infrastructure network supported by the French National Research Agency (ANR-
567 10-INSB-04, Investissement d’Avenir program) for microscope usage and assistance. We

568 thank the members of the Institut Pasteur Central Animal Facility for their assistance with
569 animal studies. I.G.B. laboratory was supported by Investissement d’Avenir program,
570 Laboratoire d’Excellence "Integrative Biology of Emerging Infectious Diseases" (ANR-10-
571 LABX-62-IBEID), by the Investissement d’Avenir program (RHU Torino Lumière ANR-16-
572 RHUS-0008), by the French National Research Agency (ANR-16-CE15-0021) and by R&D
573 grants from Danone and MEIJI.

574 M.C. was supported by grants from the Fondation pour la Recherche Médicale
575 (DEQ20130326475) and the European Union's European Regional Development Fund. We
576 thank T. Durand and MP. Fourmaux for excellent technical assistance.

577

578 **Authors’ contribution.** G.M. and M.T. performed the majority of the experimental procedures.
579 T.G. contributed to the preclinical studies in mice. M.D., T.G. and O.B. performed RT-qPCR
580 and ELISA analysis. M.D. contributed to histological analysis of colon sections. E.W.
581 performed viral genome quantification by RT-qPCR. R.W. and I.G.B. performed histological
582 analysis of tissue sections from NOD2- β -Gal reporter mice. All authors contributed to
583 interpretation of raw data and critically reviewed and/or modified the manuscript. G.M. and
584 M.C. conceived, designed and wrote the paper.

585

586 **Figures legends:**

587 **Figure 1: MNoV_S99 aggravates inflammation in DSS-induced colitis**

588 **A)**- *In vivo* experimental design, C57BL/6J mice were orally gavaged with PBS or MNoV_S99 (10^7
589 TCID₅₀PFU/mL), 7 days later, all the mice were given DSS in drinking water for a week. Mice were
590 weighed daily for weight loss comparison. **B)**- 3% DSS-induced colitis ± MNoV_S99 (n = 6). **C)**- 5%
591 DSS-induced colitis ± MNoV_S99 (n = 6). In B) and C), statistical differences were determined by 2
592 ways ANOVA test, * p < 0.05, ** p < 0.01, *** p < 0.001. **D)**- Representative images from H&E
593 staining of colon sections from mock-treated (Control) or 3% DSS ± MNoV_S99 treated mice. Insets
594 showing higher magnifications from each image are presented next to each image. **E)**- Muscle wall
595 thickness was determined with Image J from colon section images. Percentages of increase are plotted
596 after baseline subtraction relatively to the values obtained from Control mice (n = 6). **F)**- Histological
597 intestinal epithelial inflammation scores comparison between Control, 3% or 5% DSS ± MNoV_S99
598 treated mice (n = 6). **G)**- Colon length comparison between Control and 5% DSS ± MNoV_S99 treated
599 mice **H)**- IL6 secretion levels from colon explants from mock or 5% DSS ± MNoV_S99 treated mice (n
600 = 6). Statistical differences were determined with Student's t-Test in E, F, G and H.

601
602
603

604 **Figure 2: MNoV_S99 associated inflammation is NOD2 dependent**

605 Weight loss comparison in **A)**- 3% DSS-induced colitis ± MNoV_S99 in WT mice (n=6) and **B)**- in
606 *Nod2*^{-/-} mice (n=6), statistical differences were determined by 2 ways ANOVA test, * p < 0,05, ** p <
607 0,01, *** p < 0,001. **C)**- Representative images of H&E staining of colon sections from mice in A) and
608 B). Insets showing higher magnifications are presented below each image. **D)**- Percentages of increase
609 of muscle wall thickness from colon section images are plotted after baseline subtraction relatively to
610 the values obtained from WT mice treated only with DSS (n = 6), statistical differences were determined
611 with Student's t-Test.

612
613
614

615 **Figure 3: MNoV_S99 associated pro-inflammatory signalling is NOD2 and MAVS-dependent in
616 myeloid lineage cells**

617 **A)**- Representative image showing an intestinal villus from a *Nod2*^{GFP} mouse (GFP is shown in green,
618 Phalloidin in grey and DAPI in blue); scale bare represents 50µm. **B)**- Representative western blot
619 showing STAT1 signalling pathway activation after 1h infection (Moi 1) with the mentioned MNoV
620 strains in BMDM. Below are shown quantification of pSTAT1 bands intensities normalized to β-actin
621 and relative to mock-infected cells (n = 3, mean ± SEM), statistical differences were determined by 1
622 way ANOVA test * p < 0,05, ** p < 0,005. **C)**- **STAT1 activation** in response to MNoV_S99 (Moi 1 or
623 5) in BMDM from WT vs *Nod2*^{-/-} infected for 30 or 60 minutes. The lower panel shows quantification
624 of pSTAT1, bands intensities normalized to β-actin and relative to mock-infected cells (n = 3, mean ±
625 SEM). Statistical differences were determined by 2 ways ANOVA test * p < 0,05. **D)**- STAT1 activation
626 in response to MNoV_S99 (Moi 0.1) in WT or *Nod2*^{-/-} BMDM infected for 24h. Relative quantification
627 of pSTAT1 (n = 3, mean ± SEM) is shown in the lower panel, statistical differences were determined
628 by 2 ways ANOVA test *** p < 0,0005. **E)**- STAT1 activation in response to MNoV_S99 (Moi 0.1) in
629 BMDM from WT vs *Mavs*^{-/-} infected for 60 minutes. Relative quantification of pSTAT1 (n = 4, mean ±
630 SEM) are shown below. The lower panel shows the mock vs Moi 0.1 infected cells quantification of
631 pSTAT1. Statistical differences were determined by 2 ways ANOVA test * p < 0,05.

632

633 **Figure 4: NOD2 dependent noroviral load**

634 **A)**- WT, *Nod2*^{-/-} and *Atg161l*^{HM} mice (n = 5 each) were treated with 3% DSS and infected with
635 MNoV_CR6 (3.10^7 PFU). Inflammation was measured as percentage of increase in muscle thickness at
636 the anal-rectal junction in colonic section images plotted after baseline subtraction relatively to the
637 values obtained from WT mice. **B)**- The viral load measured in stools from WT, *Nod2*^{-/-} and *Atg161l*^{HM}
638 mice at day 3, 5 and 7 post-infection with MNoV_CR6 (3.10^7 PFU) (n = 8). **C)**- The viral load measured

639 from indicated tissue samples from MNoV_CR6 infected (3.10^7 PFU) WT, *Nod2*^{-/-} and *Atg16l1*^{HM} mice
 640 that were treated for 1 week with D55 3% (n = 5). **D)**- MNoV_S99 genome quantification from WT
 641 and *Nod2*^{-/-} BMDM cells infected with MNoV_S99 (Moi 0.1 for 24h) (n = 3). All the statistical
 642 differences were measured with Student's t-Test.

643
 644 **Figure 5: NOD2 dependent pro-inflammatory signalling associated with MNoV_S99 infection and
 645 bacterial MDP**

646 Quantification of *Nod2* mRNA levels measured by RT-qPCR in **A)**- in Raw264.7 cells infected with
 647 MNoV_S99 (Moi 0.1 or 1, for 24h) and in **B)**- in BMDM from WT mice (Moi 0.1, for 24h) normalized
 648 to *ActB* and relative to mock-infected cells (n = 3). **C)**- Representative western blot showing STAT1
 649 and I κ B α signalling pathways modulation in cell lysates from monocytes that were either infected with
 650 MNoV_S99 (Moi 5, 2h), treated with MDP (10ng/mL, 2h), or a combination of both. **D)**- Quantification
 651 and comparison of pSTAT1 and pI κ B α signals between MNoV_S99 infected alone cells or in
 652 combination with MDP (10ng/mL, 2h), (n = 3), with the band intensity being normalized to β -actin and
 653 relative to mock-treated cells. **E)** TNF α production by BMDC subjected to MNoV_S99's ssRNA
 654 (10 μ g/mL) alone, or supplemented with either MDP (1 μ g/mL) or MDP-DD (1 μ g/mL) overnight. **F)**
 655 TNF α production by BMDM cells infected with MNoV_S99 (Moi 0.1 or 1) for 6h, prior to being treated
 656 with MDP (10 μ g/mL) overnight. **G)** Net production of MNoV_S99 in Raw264.7 cells infected with
 657 MNoV_S99 (Moi 1 for 2h before MDP treatment (100ng/mL) for 24h). Statistical differences were
 658 analyzed with Student's t Test.

659
 660

661 **Supplementary Figures**

662

663 **Supplementary Figure 1: Analysis of MNoV_S99 associated NOD2 dependent inflammation
 664 measurements from mice showed in Figure 2**

665 **A)** Colon length comparison between WT and *Nod2*^{-/-} from 3% DSS \pm MNoV_S99 treated mice,
 666 statistical differences were determined with Student's t-Test, * p <0,02. **B)**- Histological scores
 667 comparison between WT and *Nod2*^{-/-} \pm MNoV_S99 treated mice, statistical differences were determined
 668 with Student's t-Test, * p <0,05. **C)**- TNF α production of explants (ON) from WT and *Nod2*^{-/-} 3% DSS
 669 \pm MNoV_S99 treated mice was measured by ELISA.

670

671 **Supplementary Figure 2: MNoV_S99 associated pro-inflammatory signalling pathways activation**









672 Representative western blot showing STAT1, I κ B α , AKT and ERK signalling pathways' modulation in
 673 cell lysates from Raw264.7 that were either infected with MNoV_S99 (Moi 1) for various times or mock
 674 treated for 60 min. β -actin was used as loading control.

675


676 **Tables:**

Table1: Antibodies used for Western Blotting		
Primary antibodies	Dilution	Supplier
anti-phosphoStat1 (Tyr 701) (58D6) (85kDa)	1/1000	Cell Signaling Technology
anti-Stat1(D1K9Y)(85kDa)	1/1000	
anti-phosphoI κ B α (Ser32/36) (5A5) (40kDa)	1/1000	
anti-I κ B α (44D4) (39kDa)	1/1000	
anti-phosphoAKT (Ser473) (D9E) (60kDa)	1/1000	
anti-AKT (60kDa)	1/1000	
anti-phospho44/42 MAPK (Erk1/2) (Trh202/Tyr204) (197G2) (42, 44 kDa)	1/1000	
anti-p44/42 (Erk1/2) (42, 44 kDa)	1/1000	
anti- β actin (45kDa)	1/500	
Secondary antibodies	Dilution	
anti-Rabbit_HRP (#711-035-152)	1/5000	Jackson
anti-Mouse_HRP (#115-005-003)	1/5000	Laboratories


677




A.




B.



D.



C.













Figure 4


A.




B.



C.



D.












Figure S1






Figure S2

